ENTROPY NEURODYNAMICS LIMITED — Board/Management Information 2024

Jun 25, 2024

==> picture [210 x 47] intentionally omitted <==

ASX Release 26 June 2024

Psychedelic sector pioneer Robin Carhart-Harris renews role as Scientific Advisory Board Chair

• Robin Carhart-Harris, PhD, a psychopharmacologist and globally recognised leader in psychedelics research, has renewed his role as Chair of the Company’s Scientific Advisory Board for a three-year term

• Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco and founded the Centre for Psychedelic Research at Imperial College London in April 2019 – the first such research centre of its kind globally

• As Chair of the Scientific Advisory Board, Dr. Carhart-Harris will provide oversight of the review process for new and ongoing projects across the Company’s development suite, and serve as an independent advisor to the Board

• Dr. Carhart-Harris has extensive clinical experience with respect to the application of psychedelic treatments for improved health outcomes, and has earned several major awards in the fields of neuroscience and psychopharmacology

---

Melbourne, Australia – Tryptamine Therapeutics Limited (‘ Tryp ’ or the ‘ Company ’) ( ASX: TYP ), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has agreed to terms with Dr Robin Carhart-Harris, PhD, to continue as Chair of the Company’s Scientific Advisory Board for a period of three years.

Dr. Carhart-Harris is a psychopharmacologist who currently serves as the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco (UCSF). He is globally recognised as a leader in the field of psychedelics research, and specialises in the design of brain imaging studies for psychedelic and psychoactive drug treatments including LSD, psilocybin, MDMA and DMT.

Dr. Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, which was the first of its kind globally. He is also the Director of the Psychedelics Division within the translational neuroscience center, Neuroscape, at UCSF.

His extensive clinical experience includes a clinical trial of psilocybin for treatment-resistant depression and a multimodal imaging study in first-time users of psilocybin. He also oversaw a double-blind randomized controlled trial comparing the effects of psilocybin and the SSRI escitalopram on depression that was published in the New England Journal of Medicine.

As Chair of the Scientific Advisory Board, Dr Carhart-Harris will continue to serve in an advisory capacity, including oversight of the review process for internal developments across the Company’s pipeline. He will also provide strategic consulting and occasional independent advice with respect to internal protocols and development initiatives.

Dr. Carhart-Harris earned a BSc in applied psychology and computing from Bournemouth University, an MA in psychoanalysis and contemporary science from Brunel University, and a PhD in psychopharmacology from the University of Bristol.

==> picture [210 x 47] intentionally omitted <==

Dr Carhart-Harris commented: “I am pleased to extend my role as Chair of Tryptamine Therapeutics Scientific Advisory Board for another three years. By allowing rapid initiation and termination of the psychedelic experience, as well as providing highly refined control over the depth and duration of that experience, I believe TRP-8803 has a very strong potential to shift the treatment paradigm for fibromyalgia and binge eating disorder, as well as certain types of depression, pain and obsessive-compulsive disorders.”

Chief Executive Officer, Mr. Jason Carroll said: “We’re thrilled to confirm the renewal of Dr Carhart-Harris’ role as Chair of the Scientific Advisory Board for another three-year term. As the Company advances its clinical development pathway for precision psychedelic therapies, we are committed to working with best-in-class industry leaders who can advise across all facets of the Company’s development suite. As a globally recognised leader in his field, Dr Carhart-Harris has provided valuable strategic insights in his role as SAB Chair to-date and we look forward to further leveraging his expertise in the years ahead as our clinical trial pathway progresses.”

About Tryptamine Therapeutics Limited

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.

The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%. The Company is also preparing to initiate a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited. -

ENDS

Investor & Media Contact

Jason Carroll Chief Executive Officer Tryptamine Therapeutics Limited jcarroll@tryptherapeutics.com

Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 henry.jordan@sdir.com.au

==> picture [209 x 47] intentionally omitted <==

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp’s Replacement Prospectus available at www.asx.com.au

These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.